415 related articles for article (PubMed ID: 19011598)
21. E1B 55-kDa deleted, Ad5/F35 fiber chimeric adenovirus, a potential oncolytic agent for B-lymphocytic malignancies.
Wang G; Li G; Liu H; Yang C; Yang X; Jin J; Liu X; Qian Q; Qian W
J Gene Med; 2009 Jun; 11(6):477-85. PubMed ID: 19340843
[TBL] [Abstract][Full Text] [Related]
22. Double E1B 19 kDa- and E1B 55 kDa-deleted oncolytic adenovirus in combination with radiotherapy elicits an enhanced anti-tumor effect.
Kim J; Kim PH; Yoo JY; Yoon AR; Choi HJ; Seong J; Kim IW; Kim JH; Yun CO
Gene Ther; 2009 Sep; 16(9):1111-21. PubMed ID: 19494843
[TBL] [Abstract][Full Text] [Related]
23. Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer.
Spanos WC; Nowicki P; Lee DW; Hoover A; Hostager B; Gupta A; Anderson ME; Lee JH
Arch Otolaryngol Head Neck Surg; 2009 Nov; 135(11):1137-46. PubMed ID: 19917928
[TBL] [Abstract][Full Text] [Related]
24. Synergy between expression of fusogenic membrane proteins, chemotherapy and facultative virotherapy in colorectal cancer.
Hoffmann D; Bangen JM; Bayer W; Wildner O
Gene Ther; 2006 Nov; 13(21):1534-44. PubMed ID: 16791286
[TBL] [Abstract][Full Text] [Related]
25. Oncolytic viruses and histone deacetylase inhibitors--a multi-pronged strategy to target tumor cells.
Nguyen TL; Wilson MG; Hiscott J
Cytokine Growth Factor Rev; 2010; 21(2-3):153-9. PubMed ID: 20395162
[TBL] [Abstract][Full Text] [Related]
26. Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration.
Heise C; Lemmon M; Kirn D
Clin Cancer Res; 2000 Dec; 6(12):4908-14. PubMed ID: 11156251
[TBL] [Abstract][Full Text] [Related]
27. Targeted radiotherapy for prostate cancer with an oncolytic adenovirus coding for human sodium iodide symporter.
Hakkarainen T; Rajecki M; Sarparanta M; Tenhunen M; Airaksinen AJ; Desmond RA; Kairemo K; Hemminki A
Clin Cancer Res; 2009 Sep; 15(17):5396-403. PubMed ID: 19706820
[TBL] [Abstract][Full Text] [Related]
28. Taming the Trojan horse: optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy.
Power AT; Bell JC
Gene Ther; 2008 May; 15(10):772-9. PubMed ID: 18369325
[TBL] [Abstract][Full Text] [Related]
29. Potent antitumor activity of the Ad5/11 chimeric oncolytic adenovirus combined with interleukin-24 for acute myeloid leukemia via induction of apoptosis.
Wei X; Liu L; Wang G; Li W; Xu K; Qi H; Liu H; Shen J; Li Z; Shao J
Oncol Rep; 2015 Jan; 33(1):111-8. PubMed ID: 25339149
[TBL] [Abstract][Full Text] [Related]
30. Concomitant use of Ad5/35 chimeric oncolytic adenovirus with TRAIL gene and taxol produces synergistic cytotoxicity in gastric cancer cells.
Chen L; Chen D; Gong M; Na M; Li L; Wu H; Jiang L; Qian Y; Fang G; Xue X
Cancer Lett; 2009 Nov; 284(2):141-8. PubMed ID: 19447545
[TBL] [Abstract][Full Text] [Related]
31. The emergence of combinatorial strategies in the development of RNA oncolytic virus therapies.
Nguyen TL; Tumilasci VF; Singhroy D; Arguello M; Hiscott J
Cell Microbiol; 2009 Jun; 11(6):889-97. PubMed ID: 19388908
[TBL] [Abstract][Full Text] [Related]
32. Telomerase-specific virotheranostics for human head and neck cancer.
Kurihara Y; Watanabe Y; Onimatsu H; Kojima T; Shirota T; Hatori M; Liu D; Kyo S; Mizuguchi H; Urata Y; Shintani S; Fujiwara T
Clin Cancer Res; 2009 Apr; 15(7):2335-43. PubMed ID: 19318473
[TBL] [Abstract][Full Text] [Related]
33. Head and neck cancer cells are efficiently infected by Ad5/35 hybrid virus.
Suominen E; Toivonen R; Grenman R; Savontaus M
J Gene Med; 2006 Oct; 8(10):1223-31. PubMed ID: 16941521
[TBL] [Abstract][Full Text] [Related]
34. Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP (E3-11.6K) protein.
Toth K; Tarakanova V; Doronin K; Ward P; Kuppuswamy M; Locke JE; Dawson JE; Kim HJ; Wold WS
Cancer Gene Ther; 2003 Mar; 10(3):193-200. PubMed ID: 12637940
[TBL] [Abstract][Full Text] [Related]
35. Combination of MIG (CXCL9) chemokine gene therapy with low-dose cisplatin improves therapeutic efficacy against murine carcinoma.
Zhang R; Tian L; Chen LJ; Xiao F; Hou JM; Zhao X; Li G; Yao B; Wen YJ; Li J; Zhang L; Chen XC; Luo F; Peng F; Jiang Y; Wei YQ
Gene Ther; 2006 Sep; 13(17):1263-71. PubMed ID: 16672984
[TBL] [Abstract][Full Text] [Related]
36. Impact of radiation therapy on the oncolytic adenovirus dl520: implications on the treatment of glioblastoma.
Bieler A; Mantwill K; Holzmüller R; Jürchott K; Kaszubiak A; Stärk S; Glockzin G; Lage H; Grosu AL; Gansbacher B; Holm PS
Radiother Oncol; 2008 Mar; 86(3):419-27. PubMed ID: 17967494
[TBL] [Abstract][Full Text] [Related]
37. [Oncolytic virus therapy for malignant brain tumors].
Ino Y; Todo T
Brain Nerve; 2009 Jul; 61(7):815-22. PubMed ID: 19618859
[TBL] [Abstract][Full Text] [Related]
38. Pegylated liposome-encapsulated doxorubicin and cisplatin enhance the effect of radiotherapy in a tumor xenograft model.
Harrington KJ; Rowlinson-Busza G; Syrigos KN; Vile RG; Uster PS; Peters AM; Stewart JS
Clin Cancer Res; 2000 Dec; 6(12):4939-49. PubMed ID: 11156255
[TBL] [Abstract][Full Text] [Related]
39. Transthyretin-driven oncolytic adenovirus suppresses tumor growth in orthotopic and ascites models of hepatocellular carcinoma.
Hsieh JL; Lee CH; Teo ML; Lin YJ; Huang YS; Wu CL; Shiau AL
Cancer Sci; 2009 Mar; 100(3):537-45. PubMed ID: 19134007
[TBL] [Abstract][Full Text] [Related]
40. An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer.
Fu X; Tao L; Zhang X
Cancer Gene Ther; 2007 May; 14(5):480-7. PubMed ID: 17290283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
